MX2007010001A - Marcadores farmacogenomicos para el pronostico de tumores solidos. - Google Patents

Marcadores farmacogenomicos para el pronostico de tumores solidos.

Info

Publication number
MX2007010001A
MX2007010001A MX2007010001A MX2007010001A MX2007010001A MX 2007010001 A MX2007010001 A MX 2007010001A MX 2007010001 A MX2007010001 A MX 2007010001A MX 2007010001 A MX2007010001 A MX 2007010001A MX 2007010001 A MX2007010001 A MX 2007010001A
Authority
MX
Mexico
Prior art keywords
prognosis
patients
solid tumors
treatment
gene
Prior art date
Application number
MX2007010001A
Other languages
English (en)
Inventor
Natalie C Twine
Michael E Burczynski
William L Trepicchio
Andrew J Dorner
Andrew Strahs
Frederick Immermann
Donna Slonim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007010001A publication Critical patent/MX2007010001A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion suministra metodos, sistemas y equipo para el pronostico o evaluacion de tratamiento de tumores solidos. Los Marcadores geneticos que son pronosticos de tumores solidos se pueden identificar de acuerdo con la presente invencion. El marcador de cada gen tiene patrones de expresion alterados en PBMC de los pacientes con tumor solido luego de la iniciacion de un tratamiento antineoplasico, y la magnitud de estas alteraciones se correlaciona con los resultados clinicos de estos pacientes. En una modalidad, se utiliza un modelo de riesgo proporcional Cox para determinar las correlaciones entre los resultados clinicos de pacientes RCC y los cambios de expresion genetica en PBMC de estos pacientes durante el curso de un tratamiento CCI-779. Ejemplos no limitantes de genes identificados mediante el modelo Cox se describen en las Tablas 4A, 4B, 5A y 5B. Estos genes se pueden utilizar como marcadores sustitutos para pronostico de RCC. Ellos tambien se pueden utilizar como iniciadores farmacogenomicos para la eficacia del CCI-779 u otras drogas antineoplasicas.
MX2007010001A 2005-02-18 2006-02-17 Marcadores farmacogenomicos para el pronostico de tumores solidos. MX2007010001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65408205P 2005-02-18 2005-02-18
PCT/US2006/005772 WO2006089185A2 (en) 2005-02-18 2006-02-17 Pharmacogenomic markers for prognosis of solid tumors

Publications (1)

Publication Number Publication Date
MX2007010001A true MX2007010001A (es) 2007-09-27

Family

ID=36649050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010001A MX2007010001A (es) 2005-02-18 2006-02-17 Marcadores farmacogenomicos para el pronostico de tumores solidos.

Country Status (15)

Country Link
US (1) US20090061423A1 (es)
EP (1) EP1849007A2 (es)
JP (1) JP2008529554A (es)
KR (1) KR20070115891A (es)
CN (1) CN101120255A (es)
AU (1) AU2006214078A1 (es)
BR (1) BRPI0608429A2 (es)
CA (1) CA2598393A1 (es)
CR (1) CR9298A (es)
IL (1) IL185206A0 (es)
MX (1) MX2007010001A (es)
NO (1) NO20074065L (es)
RU (1) RU2007129864A (es)
WO (1) WO2006089185A2 (es)
ZA (1) ZA200706919B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930426A4 (en) * 2005-09-02 2009-04-29 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSIS OF KIDNEY CANCER AND EVALUATION OF VITAL PROGNOSIS OF A PATIENT WITH KIDNEY CANCER
WO2008128043A2 (en) * 2007-04-11 2008-10-23 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
JP6286124B2 (ja) 2010-01-11 2018-02-28 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2903878C (en) 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
JP6427750B2 (ja) * 2013-10-02 2018-11-28 コニカミノルタ株式会社 Ｃｘｃｌ１、ならびにｓｍｏｘおよび／またはｉｄ１の発現量に基づく肺癌患者の予後を判定するためのデータ収集方法およびキット
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
EP3274467A4 (en) * 2015-03-24 2018-10-31 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN111537424B (zh) * 2020-04-26 2022-10-28 北京市神经外科研究所 基于外周血细胞评估脊髓胶质瘤患者预后性的系统
CN111640518A (zh) * 2020-06-02 2020-09-08 山东大学齐鲁医院 一种宫颈癌术后生存预测方法、系统、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
WO2002061144A2 (en) * 2001-01-31 2002-08-08 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7611839B2 (en) * 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors

Also Published As

Publication number Publication date
CR9298A (es) 2007-11-23
CN101120255A (zh) 2008-02-06
BRPI0608429A2 (pt) 2009-12-29
RU2007129864A (ru) 2009-03-27
KR20070115891A (ko) 2007-12-06
US20090061423A1 (en) 2009-03-05
AU2006214078A1 (en) 2006-08-24
WO2006089185A8 (en) 2007-09-27
IL185206A0 (en) 2008-01-06
ZA200706919B (en) 2008-06-25
CA2598393A1 (en) 2006-08-24
JP2008529554A (ja) 2008-08-07
EP1849007A2 (en) 2007-10-31
WO2006089185A3 (en) 2006-09-28
WO2006089185A2 (en) 2006-08-24
NO20074065L (no) 2007-11-14

Similar Documents

Publication Publication Date Title
MX2007010001A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos.
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2006037462A3 (en) Cancer markers
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2007009755A8 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
NZ620799A (en) Molecular diagnostic test for cancer
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
WO2012068383A3 (en) ncRNA AND USES THEREOF
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
WO2009037454A3 (en) Cancer marker and therapeutic target
BRPI0718322A2 (pt) Métodos para diagnosticar uma suscetibilidade para câncer em um indivíduo humano, para identificar um marcador para o uso na avaliação da suscetibilidade para câncer, para genotipar uma amostra de ácido nucléico, para avaliar um inidivíduo quanto a probabilidade de resposta a um agente terapêutico, para predizer o prognóstico e para monitorar o progresso de um tratamento de um indivíduo, kit para avaliar a suscetibilidade para câncer em um indivíduo, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para câncer em um indivíduo.
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
WO2011027310A8 (en) Novel tumor markers
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
ATE509933T1 (de) Pentacyclische kinaseinhibitoren